Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — FY2020 Earnings Presentation
48 slides from Daiichi Sankyo's earnings presentation, Apr 27, 2021
Slide 1: FY2020 Financial Results Presentation
FY2020 Financial Results Presentation DAIICHI SANKYO CO., LTD. Sunao Manabe President and CEO April 27, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda 1 FY2020 Financial Results 2 FY2021 Forecast 3 Business Update 4 R&D Update 5 Actions against COVID-19 Update 6 Appendix 3
Slide 4: Overview of FY2020 Results
Overview of FY2020 Results (Bn JPY) FY2019 YTD FY2020 YTD YoY Results Results -2.0% Revenue 981.8 962.5 -19.3 Cost of sales 343.2 338.3 -4.9 SG&A expenses 302.3 333.1 30.8 R&D expenses 197.5 227.4 29.9 -54.0% Operating Profit 138.8 63.8 -75.0 Profit before tax 141.2 74.1 -67.0 Profit attributable to
Slide 5: Revenue
Revenue Decreased by 19.3 Bn JPY (Decreased by 14.0 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2019 Results FY2019 Results 981.8 Japan Japan Tarlige +12.6 Memary -32.1 49.4 Japan (incl. Vaccines, (incl. Vaccines,OTC) OTC) Enhertu +4.4 Inavir -15.6 Lixiana -5.6 Daiichi Sa
Slide 6: Operating Profit
Operating Profit Decreased by 75.0 Bn JPY (Decreased by 46.3 Bn JPY excl. forex impact and special items) (Bn JPY) Revenue ‐19.3 incl. forex impact of ‐5.3 FY2019 Results FY2019 Results 138.8 Cost of Sales -15.3 (Profit increased) Revenue Revenue 0.0 19.3 Decrease by revenue decrease SG&A Expenses +
Slide 7: Special Items
Special Items (Bn JPY) FY2019 YTD FY2020 YTD YoY Results Results Restructuring costs in SC 1.3 Impairment loss Cost of sales *1 6.3 - 11.2 (intangible assets) Gain on sales of subsidiary*2 -18.8 Vaccine business loss Gain on sales of fixed assets *3 -10.6 15.0 SG&A expenses compensation 17.4 Environ
Slide 8: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Decreased by 53.1 Bn JPY (Bn JPY) Financial Income / Expenses etc. -8.1 (Profit increased) FY2019 Results FY2019 Results 129.1 • Recognition of financial income due to decrease in contingent consideration -4.7 of Ambit/quizartinib acquisition • Improvemen
Slide 9: Revenue: Major Business Units (incl. Forex Impact)
Revenue: Major Business Units (incl. Forex Impact) (Bn JPY) FY2019 YTD FY2020 YTD YoY Results Results Japan 533.5 489.1 -44.4 Daiichi Sankyo Healthcare 68.5 67.2 -1.3 Daiichi Sankyo, Inc. 32.1 47.4 +15.3 Enhertu 3.2 25.7 +22.5 Olmesartan 9.8 8.6 -1.3 Welchol 9.1 5.0 -4.1 American Regent, Inc. 130.8
Slide 10: Revenue: Major Products in Japan
Revenue: Major Products in Japan (Bn JPY) FY2019 YTD FY2020 YTD YoY Results Results Nexium ulcer treatment 79.8 77.8 -1.9 Lixiana anticoagulant 83.0 77.4 -5.6 treatment for osteoporosis/ inhibitor of the progression of Pralia bone erosion associated with rheumatoid arthritis 30.9 34.6 +3.7 Memary Al
Slide 11: FY2021 Forecast
1 FY2020 Financial Results 2 FY2021 Forecast 3 Business Update 4 R&D Update 5 Actions against COVID-19 Update 6 Appendix 11
Slide 12: FY2021 Forecast
FY2021 Forecast (Bn JPY) Revenue FY2020 FY2021 Increase factor Sales expansion of main products (Enhertu, Lixiana, Tarlige, etc.) YoY Results Forecast +2.9% Decrease Factor Termination of joint sales promotion for Nexium, Drug price revision Revenue 962.5 990.0 27.5 Cost of sales Cost of sales* 337.
Slide 13: Business Update
1 FY2020 Financial Results 2 FY2021 Forecast 3 Business Update 4 R&D Update 5 Actions against COVID-19 Update 6 Appendix 13
Slide 14: Business Update: Enhertu
ENHERTU Initiatives for Business Growth in Each Region EDOXABAN Streamlining Assets Shareholder Returns 14
Slide 15: ENHERTU: Initiatives to Maximize Value
ENHERTU®: Initiatives to Maximize Value ◆ Steady expansion in market and indication ◆ Product sales: FY2020 results 30.1 Bn JPY , FY2021 forecast 69.4 Bn JPY HER2+ Breast Cancer HER2+ Gastric Cancer 3rd Line 3rd Line Breast Gastric ➢ US ➢ JP Launched in January 2020*1 Approved in September 2020*4 ➢
Slide 16: ENHERTU: Revenue
ENHERTU®: Revenue (Bn JPY) <Reference> FY2020 FY2021 Total Results Forecast YoY Consideration Product Sales 30.1 69.4 +39.3 - Japan 4.4 13.4 +9.0 - US 25.7 50.4 +24.7 - Europe 0.0 5.4 +5.4 - ASCA - 0.2 +0.2 - 9.8 * 9.8 * 1 1 Upfront payment - 149.0 *1 *1 Regulatory milestone payment 3.5 4.8 +1.3 34.
Slide 17: Initiatives for Business Growth in Each Region
ENHERTU Initiatives for Business Growth in Each Region EDOXABAN Streamlining Assets Shareholder Returns 17
Slide 18: Initiatives for Business Growth in Each Region
Initiatives for Business Growth in Each Region Initiatives to strengthen the product portfolio and maximize product value are progressing steadily Japan Europe ◆ Prophylaxis of migraine attacks ◆ Cholesterol lowering treatment EMGALITYⓇ NILEMDO® and NUSTENDI® ➢ Launched in Apr. 2021 ➢ Launched in No
Slide 19: Edoxaban
ENHERTU Initiatives for Business Growth in Each Region EDOXABAN Streamlining Assets Shareholder Returns 19
Slide 20: LIXIANA: Growth in Japan
LIXIANAⓇ: Growth in Japan Sales ◆ No.1 sales share (FY2020 Q4: 35.0%) ◆ Revenue FY2020 results: 77.4 Bn JPY (YoY ‐5.6 Bn JPY, Previous drug price base YoY +20.2 Bn JPY) FY2021 forecast: 90.4 Bn JPY (YoY +13.0 Bn JPY) (%) 50 Decrease in sales share due to drug price revision (special expansion re-pri
Slide 21: EDOXABAN: Growth in Each Country
EDOXABAN: Growth in Each Country Volume Global revenue FY2020 results: 165.9 Bn JPY (YoY +11.9 Bn JPY) FY2021 forecast: 188.4 Bn JPY (YoY +22.4 Bn JPY) 40% 33.8% Japan 35% 32.4% S. Korea 30% 21.9% Belgium 25% 21.8% Taiwan 20% 17.9% Spain 17.8% Germany 15% 17.0% Italy 10% 13.5% UK 5% 6.9% Brazil 0% 0
Slide 22: Streamlining Assets
ENHERTU Initiatives for Business Growth in Each Region EDOXABAN Streamlining Assets Shareholder Returns 22
Slide 23: Cash Generation by Streamlining Assets
Cash Generation by Streamlining Assets During the 5-Year Business Plan period (FY2016 -FY2020), generated cash of 163.2 Bn JPY by streamlining assets FY2016 FY2017 FY2018 FY2019 FY2020 Total Results Results Results Results Results Sales proceeds 17.3 Bn JPY 14.4 Bn JPY 14.3 Bn JPY 22.0 Bn JPY 2.5 Bn
Slide 24: Shareholder Returns
ENHERTU Initiatives for Business Growth in Each Region EDOXABAN Streamlining Assets Shareholder Returns 24
Slide 25: Shareholder Returns
Shareholder Returns ◆ By dividends increase and own shares acquisition, achieved total return ratio of 105.6% for the 5-year business plan period (FY2016 – FY2020) ◆ Cancelled own shares in April 2021 Dividends ➢ Dividend per share for FY2020 (Pre-split base*1): 81 JPY (vs FY2019: 11 JPY increase) A
Slide 26: R&D Update
1 FY2020 Financial Results 2 FY2021 Forecast 3 Business Update 4 R&D Update 5 Update of Actions against COVID-19 6 Appendix 26
Slide 27: Major Progress in FY2020
Major progress in FY2020 ASCO 2021 News Flow 27
Slide 28: 3ADCs: Major Progress of Enhertu in FY2020
3ADCs: Major Progress of Enhertu® in FY2020 ◆ Started DESTINY-Breast05 study (post neoadjuvant, Ph3), HER2 among high risk, early breast cancer patients positive BC ◆ Started DESTINY-Breast07 study (1/2L, Ph1b/2, combo), a fundamental study for development in earlier treatment lines ◆ Started DESTIN
Slide 29: 3ADCs: Major Progress of Enhertu in FY2020
3ADCs: Major Progress of Enhertu® in FY2020 ◆ Started DESTINY-Gastric03 study (1/2L, Ph1b/2, combo), GC a fundamental study for development in early treatment lines ◆ Started DESTINY-Lung02 study (HER2 mutated NSCLC, 2L+, Ph2) for further evaluation of dose (5.4mg/kg) NSCLC ◆ Newly added Enhertu coh
Slide 30: 3ADCs: Major Progress of Dato-DXd in FY2020
3ADCs: Major Progress of Dato-DXd in FY2020 ◆ Started TROPION-Lung01 study (2/3L, global Ph3), the first pivotal study for Dato-DXd NSCLC (w/o actionable ◆ Started TROPION-Lung02 & TROPION-Lung04 studies mutation) aiming for earlier treatment lines (1/2L) ➢ TROPION-Lung02: Ph1, pembrolizumab combo ±
Slide 31: 3ADCs: Major Progress of HER3-DXd in FY2020
3ADCs: Major Progress of HER3-DXd in FY2020 ◆ Started HERTHENA-Lung01 study, the first pivotal study for HER3-DXd ➢ EGFR mutated NSCLC 3L, pivotal global Ph2 NSCLC ◆ Started preparation for Ph1 study in combination with osimertinib, aiming for earlier treatment lines ➢ EGFR mutated NSCLC 1/2L, globa
Slide 32: 3ADCs: Major presentations at conferences in FY2020
3ADCs: Major presentations at conferences in FY2020 ASCO ESMO SABCS WCLC Enhertu® Enhertu Enhertu Enhertu ◆ DESTINY-Breast01 ◆ DESTINY-Lung01 ◆DESTINY-Lung01 ◆DESTINY-Gastric01 (HER2 positive BC, 3L, Ph2) (HER2 overexpressing NSCLC, (HER2 mt NSCLC, 2L, Ph2) (HER2 positive GC, 3L, Ph2) 2L,Ph2) ◆ HER2
Slide 33: ASCO 2021 Advance of the Year
ASCO 2021 Advance of the Year DESTINY-Gastric01 data @ASCO 2020 DESTINY-CRC01 data @ASCO 2020 Best % Change from Baseline Events/n Median T-DXd 62/125 12.5 months (95% CI, 9.6-14.3) Physician’s 8.4 months 39/62 choice (95% CI, 6.9-10.7) HR 0.59 (95% CI, 0.39-0.88) Enhertu® DESTINY-Gastric01/CRC01 da
Slide 34: Enhertu received the Japanese Prime Minister's Award
Enhertu® received the Japanese Prime Minister’s Award Award Ceremony of the 9th Technology Management and Innovation Awards The award was given in high recognition of the following: 1. The creation of Enhertu based on the many years of knowledge and experience of new drug research & development. 2.
Slide 35: Alpha: Major Progress in FY2020
Alpha: Major Progress in FY2020 Oncology Specialty Medicine Small Molecule Oncolytic Virus ◆ Lixiana® ◆DS-1647/G47Δ Atrial fibrillation in the very elderly sNDA submission (JP) NDA submission (JP) ◆ Efient® Ischemic stroke sNDA submission (JP) DXd-ADC ◆ Tarlige® Central neuropathic pain ◆DS-6157 (GP
Slide 36: ASCO 2021 News Flow
Major progress in FY2020 ASCO 2021 News Flow 36
Slide 37: Planned Presentation at ASCO 2021
Planned Presentation at ASCO 2021(6/4 to 6/8, Virtual Meeting) ◆ Abstract available online: May 19th 5pm(EDT) ◆ Slides and posters available online: Jun 4th DESTINY-CRC01 study (HER2 positive CRC, 3L, Ph2) Colorectal ◆ Oral presentation BEGONIA study Enhertu® (TNBC 1L、Ph1b/2, durvalumab combo) Breas
Slide 38: ASCO 2021: IR Conference Call
ASCO 2021: IR Conference Call Sunao Manabe Ken Takeshita President and CEO Global R&D Head For investors located in JP Monday, June 7 - 6:30-8:00pm EDT For investors located in ex-JP Tuesday, June 8 - 7:00-8:30am EDT Content will be delivered on-demand after the meeting. 38
Slide 39: News Flow
Major Progress in FY2020 ASCO 2021 News Flow 39
Slide 40: News Flow
News Flow As or April 2021 DESTINY-CRC01:HER2 positive CRC, 3L, Ph2 DS-1647 Malignant glioma • Data presentation planned at ASCO in June 2021 /G47Δ • JP: Approval anticipated in FY2021 Q1 BEGONIA:TNBC, 1L, Ph1b/2, durvalumab combo • Data presentation planned at ASCO in June 2021 PTCL, Ph2 pivotal •
Slide 41: Actions against COVID-19 Update
1 FY2020 Financial Results 2 FY2021 Forecast 3 Business Update 4 R&D Update 5 Update of Actions against COVID-19 6 Appendix 41
Slide 42: Update of Actions against COVID-19
Update of Actions against COVID-19 ◆ Genetic(mRNA)vaccination(DS-5670) ➢ Participating in fundamental research supported by AMED*1 and pursuing the development of genetic (mRNA) vaccine using Daiichi Sankyo’s original novel nucleic acid delivery technology*2 ➢ Selected to be a provider for the MHLW’
Slide 43: Appendix
1 FY2020 Financial Results 2 FY2021 Forecast 3 Business Update 4 R&D Update 5 Update of Actions against COVID-19 6 Appendix 43
Slide 44: Major R&D Milestones in FY2021 (3ADCs)
Major R&D Milestones in FY2021 (3ADCs) As of April 2021 FY2020 FY2021 Project Target Indications [phase, study name] Q4 Q1 Q2 Q3 Q4 HER2+, 3L [P2 pivotal, DESTINY-Breast01] EU approved HER2+, 2L [P3, DESTINY-Breast03] TLR anticipated HER2 low, post chemo [P3, DESTINY-Breast04] TLR anticipated BC HER
Slide 45: Major R&D Milestones in FY2021 (Alpha)
Major R&D Milestones in FY2021 (Alpha) As of April 2021 FY2020 FY2021 Project Target Indications [phase, study name, region] Q4 Q1 Q2 Q3 Q4 Quizartinib AML, 1L [P3, JP/US/EU/Asia] TLR anticipated Pexidartinib Tenosynovial giant cell tumor [P2, JP] Study started Approval DS-1647/G47Δ Malignant glioma
Slide 46: Major R&D Pipeline: 3ADCs
Major R&D Pipeline: 3ADCs As of April 2021 Phase 1 Phase 2 Phase 3 Submitted (JP/US) NSCLC, TNBC, HR+ BC (US/EU/Asia) HER2+ BC 2L~/1L (US/EU/Asia) TNBC (JP/US/EU/Asia)HER2+ BC 3L TROPION-PanTumor01 DESTINY-Breast07 (durvalumab combo) DESTINY-Breast02 BEGONIA (JP/US/EU/Asia) NSCLC (US/EU/Asia) HER2 l
Slide 47: Major R&D Pipeline: Alpha
Major R&D Pipeline: Alpha As of April 2021 Phase 1 Phase 2 Phase 3 Submitted DS-7300 (JP/US) DS-3201 (JP/US) DS-3201 (JP) Quizartinib (JP/US/EU/Asia) DS-1647/G47Δ (JP) B7-H3-directed ADC EZH1/2 inhibitor EZH1/2 inhibitor FLT3 inhibitor Oncolytic HSV-1 Solid tumors Non-Hodgkin‘s lymphomas ATL/L 1L AM
Slide 48: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1125 Email: [email protected]
Daiichi Sankyo Company — FY2020 Earnings Presentation on 6ix